Quick Takeaways
- D. E. SHAW & CO, L.P. filed SCHEDULE 13G/A for Keros Therapeutics, Inc. Common Stock, $0.0001 par value per share (KROS).
- Disclosed ownership: 3.9%.
- Date of event: 31 Dec 2025.
D. E. SHAW & CO, L.P. - 31 Dec 2025 SCHEDULE 13G/A Report for Keros Therapeutics, Inc. Common Stock, $0.0001 par value per share (KROS)
- Filing Manager
- D. E. SHAW & CO, L.P.
- Reporting Manager
- D. E. Shaw & Co., L.P.
- Symbol
- KROS
- Shares outstanding
- 19,388,615 shares
- Disclosed Ownership
- 756,156 shares
- Ownership
- 3.9%
- Form type
- SCHEDULE 13G/A
- Filing time
- 17 Feb 2026, 16:05:40 UTC
- Date of event
- 31 Dec 2025
- Previous filing
- 27 Oct 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"D. E. SHAW & CO, L.P. disclosed 3.9% ownership in Keros Therapeutics, Inc. Common Stock, $0.0001 par value per share (KROS) on 31 Dec 2025."
What Changed
- Previous schedule filing date: 27 Oct 2025.
- Current filing was accepted on 17 Feb 2026, 16:05.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (3)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| D. E. Shaw & Co., L.P. | 3.9% | 756,156 | 0 | 756,156 | /s/ Daniel R. Marcus | Daniel R. Marcus / Chief Compliance Officer | |
| D. E. Shaw & Co., L.L.C. | 3.9% | 755,473 | 0 | 755,473 | /s/ Daniel R. Marcus | Daniel R. Marcus / Authorized Signatory | |
| David E. Shaw | 3.9% | 756,156 | 0 | 756,156 | /s/ Daniel R. Marcus | Daniel R. Marcus / Attorney-in-Fact for David E. Shaw |